Urinary Lipid Profiling for the Identification of Fabry Hemizygotes and Heterozygotes
- 1 April 2005
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 51 (4), 688-694
- https://doi.org/10.1373/clinchem.2004.041418
Abstract
Background: Fabry disease is an X-linked lysosomal storage disorder resulting from a deficiency of the lysosomal hydrolase, α-galactosidase, for which enzyme replacement therapy is now available. In this study, we aimed to identify Fabry heterozygotes not only for genetic counseling of families but because it is becoming increasingly obvious that many heterozygous (carrier) females are symptomatic and should be considered for treatment. Methods: We measured 29 individual lipid species, including ceramide, glucosylceramide, lactosylceramide, and ceramide trihexoside, in urine samples from Fabry hemizygotes and heterozygotes and from control individuals by electrospray ionization tandem mass spectrometry. Individual analyte species and analyte ratios were analyzed for their ability to differentiate the control and patient groups. Results: The Fabry hemizygotes had increased concentrations of the substrate for the deficient enzyme, ceramide trihexoside, as well as lactosylceramide and ceramide, along with decreased concentrations of both glucosylceramide and sphingomyelin. Ratios of these analytes improved differentiation between the control and Fabry groups, with the Fabry heterozygotes generally falling between the Fabry hemizygotes and the control group. Conclusions: These lipid profiles hold particular promise for the identification of Fabry individuals, may aid in the prediction of phenotype, and are potentially useful for the monitoring of therapy in patients receiving enzyme replacement.Keywords
This publication has 19 references indexed in Scilit:
- Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype1Kidney International, 2003
- Rapid quantitation of globotriaosylceramide in human plasma and urine: a potential application for monitoring enzyme replacement therapy in Anderson‐Fabry diseaseRapid Communications in Mass Spectrometry, 2002
- Fabry disease: 45 novel mutations in the α-galactosidase A gene causing the classical phenotypeMolecular Genetics and Metabolism, 2002
- Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier femalesJournal of Medical Genetics, 2001
- Characterization of Urinary Sulfatides in Metachromatic Leukodystrophy Using Electrospray Ionization-Tandem Mass SpectrometryMolecular Genetics and Metabolism, 2001
- Fabry disease: twenty novel α-galactosidase A mutations causing the classical phenotypeJournal of Human Genetics, 2001
- Jamming the endosomal system: lipid rafts and lysosomal storage diseasesTrends in Cell Biology, 2000
- Anderson-Fabry disease.BMJ, 1988
- Heterozygote detection in fabry disease utilizing multiple enzyme activitiesAmerican Journal of Medical Genetics, 1981
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959